Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pegvisomant Pfizer/Sensus.

Vincent Goffin1, Philippe Touraine

  • 1Inserm Unit 584, Hormone Targets, Faculty of Medicine Necker, 156 rue de Vaugirard, 75730, Paris Cedex 15, France. goffin@necker.fr

Current Opinion in Investigational Drugs (London, England : 2000)
|May 12, 2004
PubMed
Summary

Pegvisomant, a modified human growth hormone (hGH), treats acromegaly by blocking growth hormone receptor activation. This novel drug offers a new therapeutic option for acromegaly patients in the US and Europe.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Metabolic Risk in Childhood Brain Cancer Survivors with Childhood-Onset Growth Hormone Deficiency.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
Same author

MSH4 and MSH5 variants in premature ovarian insufficiency: A literature review and case study.

Maturitas·2026
Same author

The polystyrene beads sign: a simple MRI marker for the preoperative diagnosis of papillary hypothalamic craniopharyngiomas.

European journal of endocrinology·2026
Same author

Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review.

European urology oncology·2026
Same author

Spinal glial cell derived extra-pituitary prolactin contributes to postoperative pain in females.

Frontiers in aging neuroscience·2026
Same author

European Society for Paediatric Endocrinology and European Society of Endocrinology Joint Clinical Practice Guidance for Healthcare Transition from Paediatric to Adult Endocrine Care.

Hormone research in paediatrics·2026

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Acromegaly is a disorder caused by excess growth hormone (GH).
  • Current treatments often focus on reducing GH synthesis.

Purpose of the Study:

  • To introduce pegvisomant, a novel therapeutic agent for acromegaly.
  • To describe the mechanism of action of pegvisomant.

Main Methods:

  • Development and launch of pegylated, genetically modified human growth hormone (hGH).
  • Mechanism involves preventing GH receptor activation.

Main Results:

  • Pegvisomant effectively targets GH receptor activation.
  • Offers an alternative mechanism to somatostatin analogs.

Conclusions:

  • Pegvisomant represents a significant advancement in acromegaly treatment.
  • The drug is now available in the US and Europe.

Related Experiment Videos